EMEA-002544-PIP01-18-M01
Key facts
Invented name |
Retsevmo
|
Active substance |
Selpercatinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0398/2021
|
PIP number |
EMEA-002544-PIP01-18-M01
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Eli Lilly and Company
E-mail: EU_paediatric@lilly.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|